Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators.

Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.

2.

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R.

Br J Cancer. 2013 Aug 6;109(3):589-96. doi: 10.1038/bjc.2013.367. Epub 2013 Jul 18.

3.

Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.

Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M.

J Clin Oncol. 2012 Mar 1;30(7):722-8. doi: 10.1200/JCO.2011.36.8993. Epub 2012 Jan 23.

PMID:
22271481
4.

Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.

Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2009 Sep 15;15(18):5888-94. doi: 10.1158/1078-0432.CCR-09-0728. Epub 2009 Sep 1.

5.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C.

N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

6.

Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2008 Apr 1;14(7):2082-7. doi: 10.1158/1078-0432.CCR-07-2068.

7.

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2008 Mar 15;14(6):1767-74. doi: 10.1158/1078-0432.CCR-07-4122.

8.

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R; Austrian Breast, Colorectal Cancer Study Group (ABCSG).

Breast Cancer Res Treat. 2008 Nov;112(1):203-13. Epub 2007 Dec 22.

PMID:
18158620
9.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

PMID:
18073378
10.

Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.

Pötter R, Gnant M, Kwasny W, Tausch C, Handl-Zeller L, Pakisch B, Taucher S, Hammer J, Luschin-Ebengreuth G, Schmid M, Sedlmayer F, Stierer M, Reiner G, Kapp K, Hofbauer F, Rottenfusser A, Pöstlberger S, Haider K, Draxler W, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.

Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):334-40. Epub 2007 Mar 23.

PMID:
17363187
11.

Impact of pretreatment thrombocytosis on survival in primary breast cancer.

Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.

Thromb Haemost. 2003 Jun;89(6):1098-106.

PMID:
12783124
12.

Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.

Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; Austrian Breast And Colorectal Cancer Study Group.

Onkologie. 2003 Apr;26(2):115-9.

PMID:
12771518
13.

Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group.

Jakesz R, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, Menzel RC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Taucher S, Seifert M, Hausmaninger H; Austrian Breast & Colorectal Cancer Study Group.

Ann Surg. 2003 Apr;237(4):556-64.

14.

Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H.

J Clin Oncol. 2003 Mar 15;21(6):984-90.

PMID:
12637461
15.

[Early experience with the advanced breast biopsy instrumentation system in a multicentre study].

Kwasny W, Tausch C, Haid A, Stierer M, Konstantiniuk P, Wayand U, Sevelda P.

Gynakol Geburtshilfliche Rundsch. 2002;42(4):212-6. German.

PMID:
12373025
16.

Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.

Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G.

J Clin Oncol. 1999 Jun;17(6):1701-9.

PMID:
10561206
17.

Identification of women with early breast cancer by analysis of p43-positive lymphocytes.

Auerbach L, Hellan M, Stierer M, Rosen AC, Ausch C, Obwegeser R, Kubista E, Wolf G, Rosen HR, Panzer S.

Br J Cancer. 1999 May;80(5-6):874-8.

18.

Effect of interferon alpha-2a on hormone receptor status in patients with advanced breast cancer.

Kornek G, Reiner A, Sagaster P, Stierer M, Mayer A, Ludwig H.

Cancer Invest. 1999;17(3):189-94.

PMID:
10099657
19.

[Therapy studies of the Austrian Breast Cancer Group (ABC)].

Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Haider K, Mlineritsch B, Schmid M, Tausch C, Reiner G, Renner K, Stierer M, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Sevelda P, Dadak C, Haid A, Scholz R, Lenzhofer P, Steindorfer P, Berger A, Mischinger HJ.

Zentralbl Chir. 1998;123 Suppl 5:28-32. German.

PMID:
10063568
20.

Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations.

Wagner TM, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Petru E, Ropp E, Langbauer G, Kubista E, Scheiner O, Underhill P, Mountain J, Stierer M, Zielinski C, Oefner P.

Hum Mol Genet. 1999 Mar;8(3):413-23. Erratum in: Hum Mol Genet 1999 Apr;8(4):717-9.

PMID:
9971877
21.

Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: evaluation of discordant findings.

Stierer M, Rosen H, Weber R, Hanak H, Auerbach L, Spona J, Tüchler H.

Breast Cancer Res Treat. 1998 Jul;50(2):125-34.

PMID:
9822217
22.

Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor.

Stöger H, Samonigg H, Krainer M, Ploszczynski M, Nirnberger G, Maca S, Hehenwarter W, Wirth M, Schüller J, Vavra N, Scheithauer W, Kornek G, Stierer M, Zielinski CC.

Eur J Cancer. 1998 Mar;34(4):482-8.

PMID:
9713297
23.

Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group.

Jakesz R, Samonigg H, Gnant M, Kubista E, Steindorfer P, Hausmaninger H, Sevelda P, Tschurtschenthaler B, Fridrik M, Stierer M, Kolb R, Steger G.

Eur J Cancer. 1998 Jan;34(1):66-70.

PMID:
9624239
24.

Male breast cancer: Austrian experience.

Stierer M, Rosen H, Weitensfelder W, Hausmaninger H, Teleky B, Jakesz R, Fruhwirth H, Dünser M, Beller S, Haid A, et al.

World J Surg. 1995 Sep-Oct;19(5):687-92; discussion 692-3.

PMID:
7571664
25.

A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer.

Stierer M, Rosen H, Weber R, Hanak H, Auerbach L, Spona J, Tüchler H.

Breast Cancer Res Treat. 1995;36(1):11-21.

PMID:
7579502
26.

Flushable exo-endodrainage: a modified palliative approach to non-resectable malignant biliary obstruction.

Stierer M, Wasl H, Rosen HR, Marczell AP, Spoula H.

HPB Surg. 1993 Aug;7(1):25-32.

28.

Determination of placental ferritin-positive peripheral lymphocytes in early stages of breast cancer.

Rosen HR, Stierer M, Göttlicher J, Wolf H, Spoula H, Eibl M.

Am J Surg. 1993 Feb;165(2):213-7.

PMID:
8427398
29.

[First manifestation of non-Hodgkin's lymphoma in the labia major].

Klein M, Heinz R, Stierer M, Kühnel E, Beck A.

Zentralbl Gynakol. 1993;115(3):131-2. German.

PMID:
8465625
30.
31.

Expression of p43 in breast cancer tissue, correlation with prognostic parameters.

Rosen HR, Moroz C, Reiner A, Stierer M, Svec J, Reinerova M, Schemper M, Jakesz R.

Cancer Lett. 1992 Oct 30;67(1):35-45.

PMID:
1423243
32.

Determination of placental ferritin (PLF)-positive lymphocytes in women in early stages of breast cancer.

Rosen HR, Stierer M, Göttlicher J, Wolf H, Weber R, Vogl E, Eibl M.

Int J Cancer. 1992 Sep 9;52(2):229-33.

PMID:
1521910
33.

[Mastopathy in partial testicular feminization].

Stierer M, Rosen HR, Mrstik C, Rosen A.

Geburtshilfe Frauenheilkd. 1992 Aug;52(8):504-6. German.

PMID:
1397949
34.

Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter.

Stierer M, Rosen HR, Weber R, Marczell A, Kornek GV, Czerwenka E.

Surg Gynecol Obstet. 1992 Aug;175(2):151-60.

PMID:
1321990
36.

Nuclear pleomorphism, a strong prognostic factor in axillary node-negative small invasive breast cancer.

Stierer M, Rosen H, Weber R.

Breast Cancer Res Treat. 1992 Jan;20(2):109-16.

PMID:
1554886
37.

Non-ovarian peritoneal papillary serous carcinoma with high CA125 levels.

Rosen HR, Rosen AC, Preiser J, Stierer M, Klein M, Hanak H.

Arch Gynecol Obstet. 1992;251(4):199-202.

PMID:
1503511
38.

Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.

Rosen HR, Moroz C, Reiner A, Reinerova M, Stierer M, Svec J, Schemper M, Jakesz R.

Breast Cancer Res Treat. 1992;24(1):17-26.

PMID:
1463868
39.

Impaired primary antibody responses after vaccination against hepatitis B in patients with breast cancer.

Rosen HR, Stierer M, Wolf HM, Eibl MM.

Breast Cancer Res Treat. 1992;23(3):233-40.

PMID:
1463863
40.

Local gentamicin application for perineal wound healing following abdominoperineal rectum excision.

Rosen HR, Marczell AP, Czerwenka E, Stierer MO, Spoula H, Wasl H.

Am J Surg. 1991 Nov;162(5):438-41.

PMID:
1951905
41.

Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study.

Stierer M, Rosen HR, Forster E, Moroz C.

Breast Cancer Res Treat. 1991 Nov;19(3):283-8.

PMID:
1777647
42.
43.

Nuclear polymorphism--a prognostic parameter to evaluate local recurrence of female breast cancer.

Rosen HR, Stierer M, Weber R.

Breast Cancer Res Treat. 1990 Nov;17(1):9-13.

PMID:
2095931
44.

Serum placental isoferritin and breast cancer prognosis.

Stierer M, Rosen HR, Moroz C.

Breast Cancer Res Treat. 1990 Nov;17(1):63. No abstract available.

PMID:
2095930
45.

Histologic grading and subfactor analysis as prognostic parameters in patients with breast cancer.

Stierer M, Rosen HR, Weber R.

J Natl Cancer Inst. 1990 Sep 19;82(18):1510. No abstract available.

PMID:
2391722
46.

Synchrony of malignant lymphoma and breast cancer.

Stierer M, Rosen HR, Heinz R, Hanak H.

JAMA. 1990 Jun 6;263(21):2922-3. No abstract available.

PMID:
2160024
47.

[Breast cancer in the male--a retrospective analysis of 15 cases].

Stierer M, Spoula H, Rosen HR.

Onkologie. 1990 Apr;13(2):128-31. German.

PMID:
2197584
48.

Influence of early diagnosis on prognosis of recurrent breast cancer.

Stierer M, Rosen HR.

Cancer. 1989 Sep 1;64(5):1128-31.

PMID:
2758386
49.

[Effect of early diagnosis on the prognosis of metastatic breast cancer].

Stierer M, Rosen HR.

Wien Klin Wochenschr. 1989 Feb 17;101(4):138-42. German.

PMID:
2929158
50.

[Breast saving therapy in the small breast cancer].

Stierer M, Rosen HR.

Langenbecks Arch Chir. 1989;374(2):67-71. German.

PMID:
2704284

Supplemental Content

Loading ...
Support Center